Special Issue

Growth Factors and Receptor Tyrosine Kinases in Development, Regeneration, and Tumorigenesis (2nd Edition)

Message from the Guest Editor

Members of the family of receptor tyrosine kinases (RTKs) have been shown to have important functions in embryonal development, wound healing, and tissue homeostasis.

Many, maybe all, RTKs are activated by dimerization or oligomerization, induced by ligand binding. This results in the auto-phosphorylation of certain tyrosine residues in the intracellular parts of the receptors, creating docking sites for SH2-domain-containing molecules, as well as in the tyrosine phosphorylation of specific downstream signaling molecules. The activated signaling pathways leads to the stimulation of cell growth, survival, and migration. Over-activity, by mutation, amplification, or overexpression, of RTKs are common in tumorigenesis, and more than half of the known RTKs have been implicated as drivers of various tumors. Tyrosine kinase inhibitors have therefore been developed and are used clinically, with beneficial effects in the treatment of tumors.

This Special Issue will highlight recent developments in the normal function of RTKs and their role in disease, as well as their structural properties.

https://www.mdpi.com/journal/cancers/special_issues/ Growth_Factors_and_Receptor_Tyrosine_Kinases

Guest Editor

Prof. Dr. Carl-Henrik Heldin

Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden

Deadline for manuscript submissions

30 November 2025



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/223491

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

